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ABSTRACT
Background: The majority of people with dementia
have other long-term diseases, the presence of which
may affect the progression and management of
dementia. This study aimed to identify subgroups with
higher healthcare needs, by analysing how primary
care consultations, number of prescriptions and
hospital admissions by people with dementia varies
with having additional long-term diseases
(comorbidity).
Methods: A retrospective cohort study based on
health data from the Clinical Practice Research Datalink
(CPRD) was conducted. Incident cases of dementia
diagnosed in the year starting 1/3/2008 were selected
and followed for up to 5 years. The number of
comorbidities was obtained from a set of 34 chronic
health conditions. Service usage (primary care
consultations, hospitalisations and prescriptions) and
time-to-death were determined during follow-up.
Multilevel negative binomial regression and Cox
regression, adjusted for age and gender, were used to
model differences in service usage and death between
differing numbers of comorbidities.
Results: Data from 4999 people (14 866 person-years
of follow-up) were analysed. Overall, 91.7% of people
had 1 or more additional comorbidities. Compared with
those with 2 or 3 comorbidities, people with ≥6
comorbidities had higher rates of primary care
consultations (rate ratio (RR) 1.31, 95% CI 1.25 to
1.36), prescriptions (RR 1.68, 95% CI 1.57 to 1.81),
and hospitalisation (RR 1.62, 95% CI 1.44 to 1.83), and
higher risk of death (HR 1.56, 95% CI 1.37 to 1.78).
Discussion: In the UK, people with dementia with
higher numbers of comorbidities die earlier and have
considerably higher health service usage in terms of
primary care consultations, hospital admissions and
prescribing. This study provides strong evidence that
comorbidity is a key factor that should be considered
when allocating resources and planning care for people
with dementia.
INTRODUCTION
The provision of care to the rising number
of people living with dementia remains a
public health challenge for health systems
worldwide. In the UK, there are ∼850 000
people who are currently living with demen-
tia1 with estimated care costs equivalent to
£32 250 per person per year.2 Those diag-
nosed with dementia have signiﬁcantly
higher community-based primary care phys-
ician (general practitioner, GP) consultation
rates when compared with those with no
dementia.3 However, there is signiﬁcant vari-
ation that could be explained by patterns of
comorbidity.4–6 Dementia can complicate the
management of comorbid conditions7 and
comorbidities or their treatment can acceler-
ate the progression of dementia.8 9
Identifying which groups have the greatest
need for healthcare is essential to plan effect-
ive dementia care.10
Multimorbidity—the presence of two or
more chronic health conditions—is highly
prevalent in the population with dementia. It
has been estimated that 95% of those with
dementia have another chronic disease in
the Scottish population.11 In the USA, the
Center for Health Care Strategies found
Strengths and limitations of this study
▪ This is the first study to examine the association
between comorbidities and service usage in the
UK dementia population.
▪ A relatively large, representative number of inci-
dent cases of dementia were sampled with
insight into primary and secondary care service
usage.
▪ Provides evidence of the importance of consider-
ing comorbidities when planning dementia care
and healthcare resource allocation in the UK.
▪ There is no standard set of codes to identify
comorbidities increasing the risk of
misclassification.
▪ Outcome measures are simple and do not
capture the full nature of care provided.
Browne J, et al. BMJ Open 2017;7:e012546. doi:10.1136/bmjopen-2016-012546 1
Open Access Research
group.bmj.com on March 24, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
heterogeneous hospitalisation rates and care costs
(excluding long-term care) based on comorbidity pat-
terns, with higher rates in those with additional psychi-
atric conditions other than dementia.12 In the UK, a
strong association has been observed between multimor-
bidity and both primary care consultations and
unplanned hospitalisation in the general population.13
However, it is uncertain to what degree these ﬁndings
can be extrapolated to the dementia population.
Understanding health service usage rates is necessary
to inform the care needs of the dementia population.
The number of comorbidities could potentially be used
to inform the type and place of dementia care needed
and guide healthcare resource allocation. Using elec-
tronic health records, this study aimed to describe the
distribution of comorbidity and estimate its impact on
primary care consultations, prescriptions and hospitalisa-
tions in the UK dementia incident population. As sec-
ondary objectives, the impact of the number of
comorbidities over risk of death and the role of speciﬁc
comorbidities was also assessed.
METHODS
Study design and setting
A population-based retrospective cohort study was con-
ducted using the Clinical Practice Research Datalink
(CPRD).14 CPRD provides anonymous data from elec-
tronic health records of 674 primary care practices in
the UK. In 2013, it included 4.4 million active partici-
pants representing 6.9% of the total UK population.15
This data set contains routinely collected information
on demographics, diagnoses, medications and tests that
can be tracked back to 1987.14 The validity of CPRD for
the identiﬁcation of chronic conditions has been
described as high,15 16 with positive predictive values for
dementia that range between 80% and 90%.17 As the
vast majority of the UK population is registered with a
GP, CPRD data are generally representative of the popu-
lation as a whole. Primary care data were linked to
administrative Hospital Episodes Statistics (HES) data to
identify secondary care admissions.
Participants, exposure, outcomes and covariates
Incident cases of dementia diagnosed between 1 March
2008 and 28 February 2009 with at least 3 months of
follow-up were included in this study. Cases were identi-
ﬁed using 65 read codes that describe unspeciﬁed
dementia or any dementia subtype were used to identify
cases (see online supplementary appendix 1). Read
codes are the standard clinical terminology used by
CPRD and UK primary care more generally, and are
more extensive than the International Classiﬁcation of
Diseases (ICD)-10 system covering additional areas such
as administrative processes. Our set of codes was based
on two published dementia lists,18 19 augmented by a
manual search by an appropriately experienced clinician
of all read terms within CPRD to identify any additional
codes that ﬁtted the case deﬁnition. The minimum
3 months follow-up period aimed to decrease the risk of
confounding due to individuals being in the ﬁnal weeks
of life; during this period, consultation rates are known
to be very high and dependent on other variables not
measured reliably in this study (eg, access to palliative
care).20
We deﬁned comorbidity as the presence of one or
more chronic health conditions, excluding dementia
itself as the index condition, based on the list of long-
term conditions in UK primary care published by
Barnett et al.11 The clinical relevance and appropriate-
ness of ﬁve of the comorbidities in this list was ques-
tioned in the context of the current work, and a
decision therefore taken to drop or merge them, result-
ing in a ﬁnal list of 34 chronic conditions excluding
dementia itself (see online supplementary appendix 2).
Corresponding Read codes (including diagnostic or
administrative codes, and where relevant, medication
codes) for each condition were drawn from existing pub-
lished code lists (identiﬁed from literature review and
the code repositories in clinicalcodes.org and caliberre-
search.org) and manual searching of all possible CPRD
codes. Two experienced clinicians reviewed each set of
codes, with disagreements settled through discussion
with a further two clinicians. The prevalence of long-
term conditions based on the selected codes was
checked in a separate, random CPRD sample of 300 000
adults, and codes were reviewed and revised if necessary
where differences in prevalence were observed com-
pared with established published ﬁgures.
Information on service usage (counts of primary care
consultations, hospitalisation and numbers of medicines
prescribed) and time-to-death were obtained during the
follow-up period. Primary care practice consultations
were deﬁned as face-to-face and telephone consultations,
including unscheduled care, with multiple encounters
on a single day only counted once; the exact classiﬁcation
used is detailed in online supplementary appendix 3.
Hospital inpatient encounters were determined using
CPRD’s integrated HES data, based on dates of discharge
for all routine and unplanned hospital admissions, irre-
spective of diagnosis. Prescribing was based on a simple
count of all prescriptions issued during the follow-up
period; duration of treatment was ignored, and multiple
prescriptions for the same item were counted only once.
Additionally, time-to-death obtained from the CPRD data
was analysed as a secondary outcome to inform differ-
ences in mortality risk between exposure groups.
Finally, information on age, gender, socioeconomic
status (Index of Multiple Deprivation), primary care
practice and dementia medications (acetylcholinesterase
inhibitors and memantine) were obtained for
adjustment.
Sample size
A minimum sample size of at least 1260 persons was
required to detect a clinically relevant increase of 15%
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in primary care consultations, with 90% power and a sig-
niﬁcance level of 1%. Assuming a baseline rate of 16
consultations per person per year3 and an average
follow-up of 2.5 years,20 we needed a sample of at least
77 participants. To account for participants being clus-
tered within primary care practices, the sample size was
inﬂated using the design effect formula21 with an
intracluster correlation coefﬁcient of 0.068.21 Previous
research has shown that when patients with dementia
are categorised into groups by their number of
comorbidities (none, one, two, three or more comorbid-
ities), the group of patients with no comorbidities is the
least prevalent, and expected to be around 5% in the
study population.11 We further inﬂated the sample size
to ensure adequate representation of this smaller group.
Statistical analysis
Participants were followed from ﬁrst date of dementia
diagnosis for up to 5 years, or earlier when death or
transfer-out of CPRD occurred. Transfer-out of CPRD
(loss of follow-up) was considered a non-informative
event and participants were censored when this hap-
pened. Participants were categorised into exposure
groups based on the number of comorbidities: low
(dementia alone or only 1 additional comorbidity),
moderate (2–3 additional comorbidities), high (4–5
additional comorbidities) or very high (6 or more add-
itional comorbidities). To conduct a clinically meaning-
ful analysis, the group with the highest prevalence
(moderate, 2–3 additional comorbidities) was selected as
the reference group.
Descriptive statistics including prevalence, medians
and IQR were used to describe the distribution of
comorbidity in the study population. Using Stata V.13.1,
a multilevel negative binomial regression model account-
ing for different follow-up times was ﬁtted to obtain rate
ratios (RR) between the exposure groups for the three
service usage outcomes. Multivariable regression was
employed to adjust for key confounders, and potential
clustering of outcome by primary care practice was
accounted for by inclusion of a random intercept in the
model (second level). Adjusted RRs are reported
together with their 95% CIs. No signiﬁcant interactions
between the exposure with age or gender were found,
hence non-stratiﬁed estimates of association are
presented.
As secondary objectives RRs between comorbidities
with a 10% or greater prevalence and service usage out-
comes were calculated using a similar multivariable
negative binomial regression, adjustment was made for
age, gender and count of comorbidities with prevalence
<10%. In addition, a multivariable Cox regression model
was ﬁtted to assess the association between time-to-death
from diagnosis and number of comorbidities. The pro-
portional hazard was evaluated using log-log plots and
the Schoenfeld residuals test. HRs together with their
95% CIs are reported, with results graphically described
using a Kaplan-Meier plot.
Linkage to deprivation and hospitalisation data is not
available for around two-ﬁfths of patients in CPRD, due
to data sharing restrictions in some primary care prac-
tices. Given this high degree of missingness, imputation
was not undertaken and a complete case analysis was
conducted for these data.
RESULTS
A total of 4999 people with dementia from 581 practices
were included in this study (ﬁgure 1). Mean follow-up
time was 2.97 years providing a total of 14 866 person-
years at risk. In total, 1665 (33.3%) participants were
transferred out of CPRD during the follow-up period,
with the most frequent reason for this being transfer to
another practice (73.8%). Those who were transferred
out were older (83 vs 79 years) and had a higher mean
number of comorbidities (3.6 vs 3.1) with no differences
in gender. Mean age was 81.4 years (SD 8.1) and the
proportion of females was 65.0%. Increasing age and
socioeconomic deprivation were observed in those with
higher numbers of comorbidities (table 1). Linked hos-
pital admission data were only available on 2853
patients; there were no clinically signiﬁcant differences
in age or gender distributions of this smaller subset of
patients.
Median number of comorbidities was 3 (IQR 2–5) and
91.8% of the people included in the study were classi-
ﬁed as comorbid (dementia plus at least one other
chronic condition). The 10 most frequent comorbidities
included 6 cardiovascular-related conditions, plus
chronic pain (33.5%), depression (23.5%), hearing loss
(22.3%) and constipation (14.2%; table 2).
During the follow-up period, participants had a
median of 46 primary care consultations (IQR 23–79), 2
hospitalisations (IQR 1–3) and 162 prescriptions (IQR
65–344). Numbers of consultations, hospitalisations and
prescriptions by age, gender and comorbidity count are
shown in table 3. There was strong evidence (p<0.001)
that after adjusting for age and gender, those with very
high (≥6) numbers of comorbidities had a signiﬁcantly
higher primary care consultation rate (RR 1.31, 95% CI
1.25 to 1.36), hospital admission rate (RR 1.62, 95%
CI 1.44 to 1.83) and prescription rate (RR 1.68, 95% CI
1.57 to 1.81) when compared with the reference group
of participants with two or three comorbidities (table 3).
Further adjustment for dementia medication and socio-
economic deprivation did not produce clinically relevant
changes in the estimates.
The association of speciﬁc frequent comorbidities and
service usage is shown in table 4. Positive associations
were observed between most individual comorbidities
and service usage, with the strongest association
observed for medication prescription. In general, effect
estimates were modest and no one particular comorbid-
ity appeared to dominate in terms of the association
with the three health service usage outcomes, although
there was a tendency for medication use to be slightly
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higher, on average, with chronic pain (RR 1.51, 95% CI
1.44 to 1.59), depression (RR 1.40, 95% CI 1.32 to 1.47)
and diabetes (RR 1.39, 95% CI 1.30 to 1.49).
During the follow-up period 1850 (37.0%) participants
died. Overall death rate was 12.7 per 100 person-years.
After controlling for age and gender, there was strong evi-
dence (p<0.001) that those with high (4–5) or very high
(≥6) numbers of conditions had higher risk of death
(HR 1.18, 95% CI 1.06 to 1.32; 1.56, 1.37 to 1.78,
respectively) compared with the reference group
(ﬁgure 2). Again, further adjustment for dementia medi-
cation and deprivation did not affect these estimates.
DISCUSSION
To the best of our knowledge, this is the ﬁrst study to
quantify the association between the number of
comorbidities and health service usage in people
Figure 1 Flow of the participants through the study. CPRD, Clinical Practice Research Datalink.
Table 1 Baseline characteristics by number of comorbidities
Number of comorbidities
Low 0 or 1 Moderate 2 or 3 High 4 or 5 Very high ≥6
Number of cases (%) 1071 (21.4%) 1691 (33.8%) 1391 (27.8%) 846 (16.9%)
Female (%) 67.0% 66.8% 63.6% 61.4%
Age in years, mean (SD) 79.5 (9.2) 81.4 (7.8) 82.0 (7.8) 82.7 (7.0)
Age group (%)
<75 years 26.2 18.3 16.4 11.9
75–79 years 21.8 19.3 18.0 19.0
80–84 years 23.2 28.0 27.0 30.4
85–89 years 18.7 23.8 25.8 27.3
≥90 years 10.2 10.6 12.8 11.4
IMD quintile* (%)
First (least deprived) 24.3 25.1 24.0 20.6
Second 25.8 25.4 22.0 20.4
Third 18.7 19.8 19.4 20.9
Fourth 19.4 18.0 19.8 20.6
Fifth (most deprived) 11.8 11.7 14.8 17.5
Dementia medication† (%) 37.3 32.9 28.1 23.8
*Only 2959 observations due to missing data.
†Acetylcholinesterase inhibitors or memantine.
IMD, Index of Multiple Deprivation.
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recently diagnosed with dementia in the UK. Those with
the highest number of comorbidities (≥6) had a 31%
higher primary care consultation rate, 68% higher pre-
scription rate and 62% higher hospitalisation rate, com-
pared with those in the largest group of participants
with two or three comorbidities. These differences in
service usage rates have signiﬁcant implications in terms
of health service funding, particularly given the increas-
ing prevalence of dementia, which is the second leading
cause of mortality in the UK, accounting for 10.3% of
deaths in 2014.22 For example, in females aged 80–85
years, those with at least six additional comorbidities
had, on average, 18.8 more primary consultations, 134.9
more prescriptions and 2.1 more hospitalisations during
a 3-year period than those with two or three additional
comorbidities. Based on average costs in 2013 for a GP
consultation (£45),23 non-elective inpatient stay
(£1489)24 and net ingredient cost per prescription item
(£8.37),25 this excess service usage would have repre-
sented an estimated cost difference of £5100 per person
over 3 years.
The association between the number of comorbidities
and health service usage might be expected to depend
on the presence of speciﬁc comorbidities. Nevertheless,
when the effect of the most frequent comorbidities was
assessed, there was no clear evidence for one particular
condition predominating in terms of driving health
service usage. This may reﬂect a lack of clinical detail
about the separate conditions, such as disease severity,
but nevertheless suggests that assessing the presence of
speciﬁc comorbidities using routine data provides little
additional insight into the overall burden on health ser-
vices beyond that gained from simply looking at number
of conditions.
Although primary care is already well placed to support
patients with multimorbidity in general, there is still a
need to explore whether there are options to improve
how it responds to the needs of those with dementia, in
order to reduce higher levels of health service usage in
these patients. It is also worth considering whether
service use in these patients could be determined by
factors other than care needs, such as health service
organisation or health-seeking behaviours. Nevertheless,
the number of comorbidities was also signiﬁcantly asso-
ciated with the risk of death, which suggests that the most
comorbid individuals still have fundamentally increased
healthcare needs that have to be met.
Comparison with other studies
Our ﬁndings are similar to those reported by Boyd and
colleagues in the USA, which also reported considerable
variation in service usage rates with degree of morbidity.
Although the US study differs by assessing speciﬁc patterns,
rather than the number of conditions,12 both suggest that
comorbidity is a key factor driving this variation. Regarding
the effect of speciﬁc comorbidities, the majority of our
results were as clinically expected. Of particular note, the
lack of association of depression with hospitalisation is at
odds with some of our previous work,13 although the fact
that all participants of this study had a neuropsychiatric
condition (dementia) could potentially lead to an under-
estimate in the effect of further mental diseases. The rates
of primary care contact we observed are higher to those
found by other UK work,3 probably explained by differ-
ences in service use deﬁnition and average disease severity
inferred from higher mortality rates.
The prevalence of comorbidity found in this study
(91.7%) concurs with the 94.7% prevalence described
Table 2 Prevalence of comorbidities
Comorbidity Number Per cent Comorbidity Number Per cent
Hypertension 2667 53.4 Cancer within past 5 years 251 5.0
Painful condition 1673 33.5 Peripheral vascular disease 203 4.1
Depression 1176 23.5 Psoriasis or eczema 194 3.9
Hearing loss 1114 22.3 Migraine 192 3.8
Coronary heart disease 1079 21.6 Parkinson disease 147 2.9
Chronic kidney disease 1042 20.8 Alcohol problems 138 2.8
Stroke 859 17.2 Inflammatory arthritis† 105 2.1
Constipation 711 14.2 Epilepsy 94 1.9
Diabetes 701 14.0 Chronic sinusitis 69 1.4
Atrial fibrillation 672 13.4 Bronchiectasis 49 <1
Diverticular disease 457 9.1 Schizophrenia/psychosis 45 <1
Prostate disorders 443 25.3* Anorexia and bulimia 39 <1
Thyroid disorders 429 8.6 Irritable bowel syndrome 36 <1
Asthma 415 8.3 Chronic liver disease 30 <1
COPD 344 6.9 Substance misuse 25 <1
Heart failure 317 6.3 Multiple sclerosis 12 <1
Blindness and low vision 251 5.0 Learning disability 12 <1%
*Percentage of male participants.
†Including other connective tissue disease.
COPD, chronic obstructive pulmonary disease.
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among prevalent cases of dementia in Scotland by
Barnett et al.11 Consistent with several other studies that
describe multimorbidity patterns, hypertension was the
most frequent comorbidity.26 The prevalence of hyper-
tension (53.4%) was lower than that estimated for the
general population aged 60–80 years in a recent English
national health survey (63.7%),27 but the prevalence of
painful condition (33.5%) was high in comparison to
that observed in populations with heart disease, diabetes
and cancer (12–32%).11
Strengths and weaknesses of the study
By using electronic health records, we were able to sample
a relatively large number of incident cases of dementia,
providing a good representation of the UK population
and thus good external generalisability. We also examined
a range of outcomes, providing us with insight into
primary and secondary health service usage, including
both contact with services and provision of treatment.
However, it is also necessary to consider a number of
important limitations. As with most studies employing
primary care records, there is no standard set of codes
available to identify conditions, data quality varies across
practices15 and missing data are often present.
Misclassiﬁcation of comorbidities may or may not be asso-
ciated with degree of health service contact (eg, opportun-
istic coding of disease during a consultation), thus
increasing or decreasing, respectively, the apparent
strength of the observed association. A further limitation is
that hospital admission data were missing for 40.1% of
cases due to a lack of governance permissions for data
linkage, although we do not believe there is any reason
that linkage rates are likely to be associated with hospital
admission rates. Another limitation is our choice of hos-
pital and prescribing outcome measures. Elective hospital
admissions may reﬂect appropriate clinical care, which is
not necessarily the case with unplanned admissions.
However, we were not able to differentiate urgency of
admission using the data available. We are also unable to
tell whether admissions were potentially avoidable.
Furthermore, a crude count of medications is unable to
capture the appropriateness of treatment. Nevertheless,
such measures have the beneﬁt of simplicity and transpar-
ency, and still provide useful insights into overall service
use. Additional outcomes which would provide more
detailed insight into service use also include quality of life
and quality of service provision, but unfortunately these
were not readily available in our data set. A further limita-
tion is the potential for differential loss to follow-up
between exposure groups leading to selection bias. The
main reason for loss to follow-up was transfer to another
practice, although the reason for transfer was unknown.
Importantly, those who were transferred out were older
and with more comorbidities. If differences reﬂected indi-
viduals with poorer health being admitted to long-term
nursing or residential care facilities, we might expect the
true strength of the association between comorbidities and
service usage to be even greater than that we observed.
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Our use of incident as opposed to prevalent cases may
result in apparently lower rates of service use, due to
patients having milder dementia, although this could be
offset by a tendency for increased diagnostic recording
prompted by greater contact with health services in
patients with more advanced disease; the lack of data on
dementia severity makes this issue hard to resolve. We have
also not accounted for any potential variations in service
use over time within individuals, such as increases leading
up to death. Finally, our study only examines primary and
secondary healthcare provision, as data were not available
to allow us to quantify long-term social care needs.
Conclusions and policy implications
Our ﬁndings emphasise that comorbidity is common and
associated with substantially increased service use in the
dementia population. Although the nature of this associ-
ation follows what is clinically expected, its quantiﬁcation
provides valuable evidence to support changes in the
design of health and care services. There is evidence to
suggest that integrated care programmes based on strong
primary care services could improve the sustainability of
health systems in comorbid populations.28 However, epi-
demiological evidence of the effect of comorbidities on
people diagnosed with prevalent and high care cost dis-
eases is scarce. Based on this study, the number of
comorbidities could potentially be used to guide health-
care resource allocation. This includes ensuring the most
multimorbid are targeted by dementia-management pol-
icies addressing issues such as hospital admission avoid-
ance, long-term community medical care and medication
optimisation. Comorbidity burden may also be used to
inform decision-making relating to the type (eg, palliative
care or normal care) and place of care for people with
dementia. Therefore, the ﬁndings of this study should be
used to increase awareness of comorbidity in dementia
care and to encourage adaptation of services accordingly.
Further work evaluating patterns of comorbidities and dif-
ferent dimensions of health, such as quality of life, is also
needed to achieve a better understanding of the impact of
comorbidity on people with dementia.
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